{"id":"https://openalex.org/W2948765499","doi":"https://doi.org/10.2337/db19-1193-p","title":"1193-P: Health-Care Costs and Medication Burden in Routine Care Initiators of Empagliflozin: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study","display_name":"1193-P: Health-Care Costs and Medication Burden in Routine Care Initiators of Empagliflozin: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study","publication_year":2019,"publication_date":"2019-06-01","ids":{"openalex":"https://openalex.org/W2948765499","doi":"https://doi.org/10.2337/db19-1193-p","mag":"2948765499"},"language":"en","primary_location":{"id":"doi:10.2337/db19-1193-p","doi":"https://doi.org/10.2337/db19-1193-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db19-1193-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102890723","display_name":"Ajinkya M Pawar","orcid":"https://orcid.org/0000-0002-8585-9505","observed_orcids":["https://orcid.org/0000-0002-8585-9505"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"AJINKYA PAWAR","raw_affiliation_strings":["Boston, MA, Ingelheim, Germany, Ridgefield, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ingelheim, Germany, Ridgefield, CT","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044474781","display_name":"Elisabetta Patorno","orcid":"https://orcid.org/0000-0002-8809-9898","observed_orcids":["https://orcid.org/0000-0002-8809-9898"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ELISABETTA PATORNO","raw_affiliation_strings":["Boston, MA, Ingelheim, Germany, Ridgefield, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ingelheim, Germany, Ridgefield, CT","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037108542","display_name":"Anouk D\u00e9ruaz\u2010Luyet","orcid":"https://orcid.org/0000-0001-7396-7392","observed_orcids":["https://orcid.org/0000-0001-7396-7392"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ANOUK DERUAZ-LUYET","raw_affiliation_strings":["Boston, MA, Ingelheim, Germany, Ridgefield, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ingelheim, Germany, Ridgefield, CT","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036238582","display_name":"Kimberly Goodnow Brodovicz","orcid":"https://orcid.org/0000-0001-8275-1649","observed_orcids":["https://orcid.org/0000-0001-8275-1649"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"KIMBERLY BRODOVICZ","raw_affiliation_strings":["Boston, MA, Ingelheim, Germany, Ridgefield, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ingelheim, Germany, Ridgefield, CT","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104039732","display_name":"ANASTASIA V. USTYUGOVA","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ANASTASIA V. USTYUGOVA","raw_affiliation_strings":["Boston, MA, Ingelheim, Germany, Ridgefield, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ingelheim, Germany, Ridgefield, CT","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110661941","display_name":"Nileesa Gautam","orcid":"https://orcid.org/0009-0002-3643-433X","observed_orcids":["https://orcid.org/0009-0002-3643-433X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"NILEESA GAUTAM","raw_affiliation_strings":["Boston, MA, Ingelheim, Germany, Ridgefield, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ingelheim, Germany, Ridgefield, CT","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030822229","display_name":"Lily Gui Bessette","orcid":"https://orcid.org/0000-0003-1088-8579","observed_orcids":["https://orcid.org/0000-0003-1088-8579"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"LILY G. BESSETTE","raw_affiliation_strings":["Boston, MA, Ingelheim, Germany, Ridgefield, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ingelheim, Germany, Ridgefield, CT","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004416630","display_name":"Sebastian Schneewei\u00df","orcid":"https://orcid.org/0000-0003-2575-467X","observed_orcids":["https://orcid.org/0000-0003-2575-467X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"SEBASTIAN SCHNEEWEISS","raw_affiliation_strings":["Boston, MA, Ingelheim, Germany, Ridgefield, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ingelheim, Germany, Ridgefield, CT","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044094148","display_name":"Mehdi Najafzadeh","orcid":"https://orcid.org/0000-0003-4503-1057","observed_orcids":["https://orcid.org/0000-0003-4503-1057"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"MEHDI NAJAFZADEH","raw_affiliation_strings":["Boston, MA, Ingelheim, Germany, Ridgefield, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ingelheim, Germany, Ridgefield, CT","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2035,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.57542865,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":93},"biblio":{"volume":"68","issue":"Supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.00279999990016222,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/empagliflozin","display_name":"empagliflozin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9039999842643738},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9879999756813049},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.734000027179718},{"id":"https://openalex.org/keywords/pill-burden","display_name":"medication burden","score":0.9850000143051147},{"id":"https://openalex.org/keywords/comparative-effectiveness","display_name":"comparative effectiveness","score":0.5929999947547913},{"id":"https://openalex.org/keywords/emprise","display_name":"emprise","score":0.625},{"id":"https://openalex.org/keywords/medicare","display_name":"Medicare","score":0.3959999978542328},{"id":"https://openalex.org/keywords/pharmacy-costs","display_name":"pharmacy costs","score":0.5630000233650208},{"id":"https://openalex.org/keywords/cardiovascular-disease-history","display_name":"cardiovascular disease history","score":0.828000009059906},{"id":"https://openalex.org/keywords/drug-use-initiation","display_name":"drug initiation","score":0.3779999911785126},{"id":"https://openalex.org/keywords/propensity-score-matching","display_name":"propensity score matching","score":0.5559999942779541},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.5529999732971191},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.6589999794960022}],"concepts":[{"id":"https://openalex.org/C2775887513","wikidata":"https://www.wikidata.org/wiki/Q5373824","display_name":"Empagliflozin","level":4,"score":0.9422523975372314},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7945955991744995},{"id":"https://openalex.org/C2780652884","wikidata":"https://www.wikidata.org/wiki/Q5323607","display_name":"EMPA","level":3,"score":0.6617898941040039},{"id":"https://openalex.org/C104863432","wikidata":"https://www.wikidata.org/wiki/Q614304","display_name":"Pharmacy","level":2,"score":0.5756068825721741},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.5091325640678406},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.4324483871459961},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3633137345314026},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.3548831343650818},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.3455151319503784},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.31514373421669006},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.11301451921463013},{"id":"https://openalex.org/C199289684","wikidata":"https://www.wikidata.org/wiki/Q83353","display_name":"Mineralogy","level":1,"score":0.0},{"id":"https://openalex.org/C138411078","wikidata":"https://www.wikidata.org/wiki/Q911272","display_name":"Electron microprobe","level":2,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/db19-1193-p","doi":"https://doi.org/10.2337/db19-1193-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db19-1193-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4381377493","https://openalex.org/W2955861752","https://openalex.org/W4225264667","https://openalex.org/W4399998154","https://openalex.org/W4399689919","https://openalex.org/W4312527590","https://openalex.org/W4415243731","https://openalex.org/W4307777306","https://openalex.org/W3035526805","https://openalex.org/W3025411223"],"abstract_inverted_index":{"EMPRISE":[0],"studies":[1],"the":[2,164],"comparative":[3],"effectiveness,":[4],"safety":[5],"and":[6,16,31,76,130,181,185],"health":[7],"care":[8,46],"resource":[9],"utilization":[10],"of":[11,59,99,158,168],"empagliflozin":[12],"(EMPA)":[13],"in":[14,44,135,189],"Medicare":[15],"2":[17,50],"U.S.":[18],"commercial":[19],"claims":[20],"datasets":[21],"(2014-2019).":[22],"In":[23],"this":[24],"first":[25,165],"analysis,":[26],"we":[27,170],"evaluated":[28],"healthcare":[29],"costs":[30,125,132],"medications":[32],"burden":[33,78,188],"associated":[34],"with":[35,48,90,96],"EMPA":[36,66,82,112,136,145,190],"vs.":[37,83,113,117,191],"dipeptidyl":[38],"peptidase":[39],"4":[40],"inhibitors":[41],"(DPP-4i)":[42],"use":[43],"routine":[45],"patients":[47,61],"type":[49],"diabetes":[51],"(T2D).":[52],"We":[53,85],"identified":[54,86],"a":[55],"1:1":[56],"propensity-score-matched":[57],"cohort":[58],"T2D":[60],"\u226518":[62],"years":[63,167],"initiating":[64],"either":[65],"or":[67],"DPP-4i":[68],"between":[69],"08/2014-09/2016.":[70],"Total":[71],"(inpatient,":[72],"outpatient,":[73],"pharmacy)":[74],"cost":[75,108],"medication":[77,139,187],"were":[79,133,141,161],"compared":[80],"for":[81],"DPP-4i.":[84],"17,549":[87],"matched":[88],"pairs":[89],"balanced":[91],"baseline":[92],"characteristics":[93],"(Table":[94],"1)":[95],"mean":[97],"follow-up":[98],"5.4":[100],"months.":[101],"Per":[102],"member":[103],"per":[104],"year":[105],"(PMPY)":[106],"total":[107,173],"was":[109],"similar":[110,172],"among":[111,144],"DDP4i":[114,192],"initiators":[115,146],"($17,771":[116],"$17,814;":[118],"Diff=":[119],"-$43,":[120],"95%":[121,151],"CI:":[122,152],"-1,380\u25001,295).":[123],"Medical":[124],"tended":[126],"to":[127],"be":[128],"lower":[129,143,179,186],"pharmacy":[131,183],"higher":[134,182],"initiators.":[137,193],"Distinct":[138],"prescriptions":[140],"slightly":[142],"[Incidence":[147],"rate":[148],"ratio":[149],"0.97,":[150],"0.96\u25000.98].":[153],"Results":[154],"stratified":[155],"by":[156,176],"history":[157],"CV":[159],"disease":[160],"consistent.":[162],"Within":[163],"two":[166],"EMPRISE,":[169],"observed":[171],"cost,":[174],"driven":[175],"trend":[177],"towards":[178],"medical":[180],"costs,":[184],"Disclosure":[194],"A.":[195,214],"Pawar:":[196],"None.":[197,244,247],"E.":[198],"Patorno:":[199],"Research":[200],"Support;":[201],"Self;":[202,209,217,229,237,251,258],"National":[203],"Institute":[204],"on":[205],"Aging.":[206],"Other":[207],"Relationship;":[208],"Boehringer":[210,218,230,238,261],"Ingelheim":[211,219,231,239,262],"International":[212,220,240],"GmbH.":[213,221,241],"Deruaz-Luyet:":[215],"Employee;":[216,222,228,236],"Spouse/Partner;":[223],"Medtronic,":[224],"Sanofi.":[225],"K.":[226],"Brodovicz:":[227],"Pharmaceuticals,":[232],"Inc.":[233],"A.V.":[234],"Ustyugova:":[235],"N.":[242],"Gautam:":[243],"L.G.":[245],"Bessette:":[246],"S.":[248],"Schneeweiss:":[249],"Consultant;":[250,257],"Aetion,":[252],"WHISCON,":[253],"LLC.":[254],"M.":[255],"Najafzadeh:":[256],"Epigenomics.":[259],"Funding":[260]},"counts_by_year":[{"year":2020,"cited_by_count":1}],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2019-06-14T00:00:00"}